Kedudukan dalam Saham
#29601
Ulisse Biomed S.p.A. is an Italy-based biotechnology enterprise specializing in... Ulisse Biomed S.p.A. is an Italy-based biotechnology enterprise specializing in healthcare diagnostics. The company develops and markets a diverse range of innovative platforms and products designed for disease detection. Central to its offerings is the Sagitta platform, which encompasses specialized tests such as Ladymed/HPV Selfy for human papillomavirus screening, CoronaMelt for identifying SARS-CoV-2, and CoronaMelt Var for detecting and genotyping SARS-CoV-2 variants. Sagitta also provides UlisseFaster, a vital reagent used for the pre-treatment of biological samples, alongside various diagnostic tools for sexually transmitted infections and for detecting HPV associated with oropharyngeal cancers. Beyond Sagitta, Ulisse Biomed boasts the NanoHybrid platform, an advanced multi-modal biomolecule system that utilizes DNA/PNA technology to directly identify specific antibodies and protein analytes from serum or whole blood samples. Its portfolio is further enhanced by the Aptavir platform, dedicated to the development and manufacturing of synthetic nucleic acid molecules aimed at curtailing the infectiousness of pathogens. Established in 2015, Ulisse Biomed S.p.A. operates from its headquarters in Udine, Italy.
Harga Saham
$0.93739396
Disegerakkan terakhir: 2026-01-08
Perubahan (1 tahun)
-6.88%
Perdagangan Ulisse Biomed S.p.A. (UBM)
Hasil untuk Ulisse Biomed S.p.A. (UBM)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada Ulisse Biomed S.p.A., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Ulisse Biomed S.p.A. dari 2026 hingga 2026
Hasil pada akhir setiap tahun
| Tahun |
Hasil |
Ubah |
|
Tidak cukup data untuk tarikh yang disediakan. |
Hasil untuk syarikat atau pesaing serupa
| Syarikat |
Hasil |
Perbezaan Hasil |
Negara |
|
|
$12.62B |
-
|
US
|
|
|
$6.02B |
-
|
NL
|
|
|
$2.23B |
-
|
US
|
|
|
$15.70B |
-
|
AU
|
|
|
- |
-
|
CH
|